OpenPayer

This document is a consolidated list of upcoming policies open for stakeholder feedback through March 5, 2026. It explicitly identifies policies relevant to orthopedics and musculoskeletal care within the list, including 7.01.176 (Suture Button Suspensionplasty Fixation System for Thumb Carpometacarpal Osteoarthritis), 7.01.550 (Knee Arthroplasty in Adults), 7.01.573 (Hip Arthroplasty in Adults), 7.01.590 (Shoulder Arthroplasty), and 8.01.52 (Orthopedic Applications of Stem Cell Therapy (Including Allografts and Bone Substitutes Used with Autologous Bone Marrow)). The document itself is formatted as a request for comment rather than a description of finalized coverage changes.

No specific language changes, coverage criteria, CPT codes, utilization management details, or clinical criteria are provided in the source text. The only concrete new or changed element presented is the solicitation deadline: “Please submit your feedback by March 5, 2026.” As such, the "what changed" element in this revision is the announcement of these listed policies being open for review and the associated comment deadline.

The document lists multiple orthopedic and musculoskeletal-related policies among the items open for review. Specifically, it enumerates the following orthopedics-relevant policy numbers and titles: 7.01.176 Suture Button Suspensionplasty Fixation System for Thumb Carpometacarpal Osteoarthritis; 7.01.550 Knee Arthroplasty in Adults; 7.01.573 Hip Arthroplasty in Adults; 7.01.590 Shoulder Arthroplasty; and 8.01.52 Orthopedic Applications of Stem Cell Therapy (Including Allografts and Bone Substitutes Used with Autologous Bone Marrow). These entries indicate that Premera-Blue Cross is soliciting feedback on a spectrum of surgical and biologic interventions relevant to musculoskeletal care.

The inclusion of both device/procedure-specific policies (e.g., suture button suspensionplasty) and broader application areas (e.g., stem cell therapy and arthroplasty policies) suggests the review cycle encompasses diverse orthopedics topics from small-joint procedures to major joint replacements and biologic adjuncts. The source text does not provide the content of each policy, only their identifiers and titles.

Within the listed items, regenerative and biologic therapies are explicitly represented by 8.01.52 "Orthopedic Applications of Stem Cell Therapy (Including Allografts and Bone Substitutes Used with Autologous Bone Marrow)." This signals that Premera-Blue Cross is seeking commentary on coverage or clinical policy positions related to stem cell therapy and related graft/substitute products when used in orthopedic indications. The source text does not provide the substantive policy position, clinical criteria, or any definitions for these therapies — only that the policy is part of the review package.

Separately, 2.01.543 "Recombinant and Autologous Platelet-Derived Growth Factors for Wound Healing and Other Non-Orthopedic Conditions" is listed among non-orthopedic biologic wound-healing items, indicating a broader review of biologic and regenerative modalities across surgical and wound care domains. Again, no coverage determinations or criteria are included in the document.

The package includes major joint replacement policies: 7.01.550 Knee Arthroplasty in Adults, 7.01.573 Hip Arthroplasty in Adults, and 7.01.590 Shoulder Arthroplasty. Their presence in the list indicates these core musculoskeletal service lines are part of the review cycle. The source text does not disclose any potential modifications to indications, age limits, or prosthetic technology coverage; it only signals these policies are available for stakeholder input.

Also noted is 7.01.176 addressing a specific technique/device for thumb carpometacarpal osteoarthritis — the Suture Button Suspensionplasty Fixation System — which highlights attention to emerging or device-specific surgical solutions for small-joint arthritis within the review set. No clinical detail, coding, or coverage stance for that device is provided in the source text.

The source document functions primarily as an announcement of multiple policies across clinical areas that are open for stakeholder feedback by the stated deadline. It includes items outside orthopedics as well (for example, 1.01.508 Negative Pressure Wound Therapy in the Outpatient Setting; 1.01.528 Hearing Aids; multiple hematopoietic cell transplantation policies in the 8.01.xx series), illustrating that the review package spans surgical, medical, and diagnostic domains.

No explanatory materials, proposed language changes, evidence summaries, or draft coverage criteria accompany this list in the provided text. Therefore, the document's substantive content is limited to policy identifiers, titles, and the public comment deadline of March 5, 2026.